AIM ImmunoTech Inc. AIM
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. We have established
a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon
to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment
Last close
0.16
2026-10-23
Market cap
$4.8M
2026-06-30 share count
52-week range
0.15 - 2.72
Valuation FY2025 figures against the last close
P/S54.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.62
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0K | $170.0K | $202.0K | $141.0K | $135.0K | $163.0K | $140.0K | $367.0K | $437.0K | $92.0K |
| R&D | $3.9M | $6.2M | $10.9M | $7.0M | $7.7M | $5.7M | $4.7M | $4.8M | $4.1M | $5.1M |
| SG&A | $7.7M | $13.7M | $21.1M | $13.1M | $8.7M | $8.7M | $7.0M | $6.2M | $6.6M | $7.7M |
| Total operating expenses | $11.8M | $19.9M | $32.1M | $20.1M | $19.0M | $15.3M | $12.6M | $11.9M | $11.9M | $13.9M |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M | -$18.8M | -$15.2M | -$12.4M | -$11.5M | -$11.4M | -$13.8M |
| Interest expense | $812.0K | $585.0K | — | — | $67.0K | $672.0K | $427.0K | $201.0K | — | — |
| Pre-tax income | -$14.0M | — | — | — | — | — | — | — | — | — |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M | -$19.1M | -$14.4M | -$9.4M | -$9.8M | -$8.3M | -$7.5M |
| EPS, basic | -8.62 | -30.92 | -0.60 | -0.40 | -0.40 | — | — | — | — | — |
| EPS, diluted | -8.62 | -30.92 | -0.60 | -0.40 | -0.40 | -0.45 | -2.58 | -9.77 | -0.29 | -0.34 |
| Shares, diluted (wtd. avg.) | 1.6M | 560,169 | 48.6M | 48.0M | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.0M | $1.7M | $5.4M | $27.1M | $32.1M | $38.5M | $1.5M | $299.0K | $1.4M | $2.4M |
| Short-term investments | $62.0K | $2.3M | $7.6M | $7.1M | $16.2M | $501.0K | $7.3M | — | — | — |
| Receivables | $7.0K | — | $1.2M | $1.7M | — | $34.0K | $44.0K | $235.0K | $24.0K | — |
| Total current assets | $3.3M | $4.2M | $14.6M | $36.3M | $50.2M | $40.3M | $10.4M | $3.8M | $3.5M | $6.9M |
| Property, plant and equipment | $71.0K | $108.0K | $127.0K | $195.0K | $4.0M | $6.5M | $7.1M | $7.8M | $8.6M | $9.5M |
| Other intangibles | $1.7M | $2.6M | $2.3M | $1.9M | $2.0M | $1.5M | $1.2M | $911.0K | $858.0K | $872.0K |
| Total assets | $5.8M | $8.6M | $19.4M | $40.5M | $57.7M | $64.6M | $20.8M | $13.8M | $14.2M | $18.9M |
| Accounts payable | $1.6M | $6.4M | $6.4M | $377.0K | $198.0K | $383.0K | $472.0K | $680.0K | $741.0K | $887.0K |
| Short-term debt | $3.5M | $2.3M | — | — | — | $230.0K | $214.0K | $199.0K | — | — |
| Total current liabilities | $6.2M | $9.5M | $8.7M | $1.4M | $673.0K | $1.1M | $1.1M | $5.3M | $2.7M | $2.4M |
| Long-term debt | $927.0K | $2.8M | — | — | — | $1.9M | $2.1M | $2.3M | — | — |
| Total liabilities | $15.6M | $9.9M | $9.1M | $2.0M | — | — | — | — | — | — |
| Retained earnings | -$440.8M | -$426.8M | -$409.5M | -$380.5M | -$361.1M | -$342.0M | -$327.6M | -$318.6M | -$308.8M | -$300.5M |
| Total equity | -$9.8M | -$1.3M | $10.2M | $38.5M | $56.9M | $61.3M | $13.4M | $5.6M | $8.7M | $15.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$14.9M | -$21.3M | -$16.1M | -$14.0M | -$10.4M | -$9.1M | -$10.6M | -$7.9M | -$7.4M |
| Depreciation and amortisation | $37.0K | $37.0K | $39.0K | $38.0K | $659.0K | $665.0K | $735.0K | $856.0K | $948.0K | $1.1M |
| Stock-based compensation | $60.0K | $686.0K | $243.0K | $954.0K | $1.6M | $1.0M | $853.0K | $929.0K | $571.0K | $52.0K |
| Capital expenditure | — | $18.0K | — | $86.0K | $41.0K | $22.0K | $68.0K | $51.0K | $20.0K | $160.0K |
| Investing cash flow | $1.9M | $4.7M | -$832.0K | $11.0M | -$631.0K | -$9.2M | -$6.1M | $92.0K | $2.7M | $2.9M |
| Financing cash flow | $10.4M | $6.4M | $485.0K | $80.0K | $8.2M | $56.6M | $16.4M | $9.4M | $4.2M | $4.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013301.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92.0K | $437.0K | $367.0K | $140.0K | $163.0K | $135.0K | $141.0K | $202.0K | $170.0K | $88.0K |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$7.5M | -$8.3M | -$9.8M | -$9.4M | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed Item 1.01
- Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
- Material agreement terminated Item 1.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |